> Kamada released a note at TASE that they received a positive review regarding its program to test its inhaled AAT in phase II clinical trials for the treatment of Cystic Fibrosis.<
Good luck with that! Bayer and PPL tried this several years ago but couldn’t make it work (#msg-1603472). Regards, Dew
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.